. Flexor tendon injuries in zone II of the hand are prone to debilitating adhesions, a form of scar tissue that obstructs gliding of the flexor tendons, severely impairing hand function. There are presently no pharmacologic treatments for the prevention or resolution of tendon adhesions, which still occur in as high as 30% of flexor tendon repairs, despite advances in surgical techniques and post-operative rehabilitation. Therefore, there is an unmet need for a mechanistic understanding of scar etiology in flexor tendons that could lead to the identification of new therapies. In the previous funding period, we established that disruption of canonical TGF-beta signaling in Smad3 knockout mice reduced flexor tendon adhesions but also reduced the tensile strength of the repair tissue. However, the differential effects of TGF-beta on activating peritendinous and intratendinous fibrosis remain unknown, and could be key to identifying novel profibrotic cellular and molecular mechanisms. To address this gap in knowledge, we will first utilize tamoxifen inducible gene deletion mouse models to investigate the effects of loss of canonical TGF-beta signaling in peritendinous versus intratendinous fibroblasts on zone II flexor tendon adhesions (Aim1). Towards the identification of downstream signaling mediators of fibrosis, we demonstrated that TGF-beta upregulates the protease- suppressor, plasminogen activator inhibitor 1 (PAI-1), which inhibits plasmin-mediated MMP activation. Furthermore, we demonstrated that PAI-1 loss of function nullifies TGF-beta1 inhibition of protease (plasmin and MMP) activity, without reducing cell proliferation. Thus, we hypothesize that PAI-1 activity does not affect cell proliferation and flexor tendon healing, but inhibits protease (plasmin and MMP) activity leading to impaired remodeling and increased adhesions. This hypothesis will be tested in Aim 2 by examining flexor tendon healing in mouse models of PAI- 1 loss- and gain-of-function. Collectively, our data suggest that targeting TGF-beta directly might be therapeutically untenable in load-bearing tendons due to its dichotomous effects, which include the indispensible PAI-1-independent effect of activating cell proliferation and matrix synthesis necessary for healing, and the pathogenic effect of inhibiting protease activity via canonical induction of PAI-1. Thus, we hypothesize that localized therapeutic inhibition of PAI-1, irrespective of its cell source, will ameliorate tendon adhesions without adversely affecting repair strength.
In Aim 3, we will test this hypothesis by optimizing and investigating the efficacy of an innovative nanoparticle-mediated siRNA delivery system against PAI-1 in zone II flexor tendon injuries in wild type mice. The proposed studies will elucidate the mechanisms by which canonical TGF-beta signaling differentially activates peritendinous fibroblasts leading to extrinsic fibrosis (Aim 1), demonstrate that canonical TGF-beta induction of PAI-1 precipitates fibrotic adhesions (Aim 2), and establish localized, transient nanoparticle-mediated delivery of siRNA to inhibit PAI-1 as a translational, strength-sustaining, anti-adhesion therapy for flexor tendon repair (Aim 3).

Public Health Relevance

Injuries in the hand typically involve flexor tendon lacerations. Repair of these tendon injuries often results in debilitating scarring and adhesions, which severely limit the function of the hand. There are presently no pharmacologic or biologic treatments for the prevention or resolution of tendon adhesions. In the previous funding period, we identified a therapeutic target that is potentially involved in the suppression of tissue remodeling and the accumulation of scar tissue. In this application, we will map out the mechanism of involvement of this therapeutic target, and investigate the efficacy of novel methodologies to inhibit its effects in a preclinical model of flexor tendon repairs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR056696-07
Application #
9144719
Study Section
Musculoskeletal Tissue Engineering Study Section (MTE)
Program Officer
Wang, Fei
Project Start
2009-07-01
Project End
2020-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Rochester
Department
Orthopedics
Type
School of Medicine & Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Wang, Yuchen; Zhang, Sue; Benoit, Danielle S W (2018) Degradable poly(ethylene glycol) (PEG)-based hydrogels for spatiotemporal control of siRNA/nanoparticle delivery. J Control Release 287:58-66
Wang, Yuchen; Newman, Maureen R; Benoit, Danielle S W (2018) Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: A review. Eur J Pharm Biopharm 127:223-236
Malcolm, Dominic W; Varghese, Jomy J; Sorrells, Janet E et al. (2018) The Effects of Biological Fluids on Colloidal Stability and siRNA Delivery of a pH-Responsive Micellar Nanoparticle Delivery System. ACS Nano 12:187-197
Freeberg, Margaret A T; Farhat, Youssef M; Easa, Anas et al. (2018) Serpine1 Knockdown Enhances MMP Activity after Flexor Tendon Injury in Mice: Implications for Adhesions Therapy. Sci Rep 8:5810
Ackerman, Jessica E; Best, Katherine T; O'Keefe, Regis J et al. (2017) Deletion of EP4 in S100a4-lineage cells reduces scar tissue formation during early but not later stages of tendon healing. Sci Rep 7:8658
Wang, Yuchen; Malcolm, Dominic W; Benoit, Danielle S W (2017) Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing. Biomaterials 139:127-138
Malcolm, Dominic W; Freeberg, Margaret A T; Wang, Yuchen et al. (2017) Diblock Copolymer Hydrophobicity Facilitates Efficient Gene Silencing and Cytocompatible Nanoparticle-Mediated siRNA Delivery to Musculoskeletal Cell Types. Biomacromolecules 18:3753-3765
Wang, Yuchen; Newman, Maureen R; Ackun-Farmmer, Marian et al. (2017) Fracture-Targeted Delivery of ?-Catenin Agonists via Peptide-Functionalized Nanoparticles Augments Fracture Healing. ACS Nano 11:9445-9458
Malcolm, Dominic W; Sorrells, Janet E; Van Twisk, Daniel et al. (2016) Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis. Bioeng Transl Med 1:193-206
Loiselle, Alayna E; Yukata, Kiminori; Geary, Michael B et al. (2015) Development of antisense oligonucleotide (ASO) technology against Tgf-? signaling to prevent scarring during flexor tendon repair. J Orthop Res 33:859-66

Showing the most recent 10 out of 32 publications